Earnings Beats

Earnings Beats Recent News

Resources Connection Beats Q4 Earnings and Revenue Estimates
Resources Connection (NYSE: RGP) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.44 per share a year ago. These figures are adjusted for non-recurring items.
What's in Store for Helmerich & Payne in Q3 Earnings?
Helmerich & Payne, Inc. (NYSE: HP) is set to release fiscal third-quarter earnings on Jul 24, after the closing bell. The current Zacks Consensus Estimate for earnings is pegged at 77 cents per share on revenues of $668.8 million.
Huntington Bancshares Q2 Earnings and Revenues Beat Estimates
Huntington Bancshares (NASDAQ: HBAN) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.35 per share a year ago. These figures are adjusted for non-recurring items.
Fifth Third Bancorp Q2 Earnings Beat Estimates
Fifth Third Bancorp (NASDAQ: FITB) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.
Intuitive Surgical Q2 Earnings: Revenue Beat, EPS Beat, Da Vinci Procedures Jump 17% — 'Pleased By Feedback On Da Vinci 5'
Intuitive Surgical reported second-quarter revenue of $2.01 billion, beating the consensus estimate of $1.97 billion. The robotic-assisted surgery company reported quarterly adjusted earnings of $1.78 per share, beating analyst estimates of $1.54 per share.
Alterity Up on Interim Data From Advance MSA Study
Shares of Alterity Therapeutics (NASDAQ: ATHE) were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for treating patients with multiple system atrophy, a rare neurodegenerative disease.
What's in the Offing for Union Pacific in Q2 Earnings?
Union Pacific Corporation (NYSE: UNP) is scheduled to report second-quarter 2024 results on Jul 25 before market open.
Cintas Surpasses Q4 Earnings and Revenue Estimates
Cintas (NASDAQ: CTAS) came out with quarterly earnings of $3.99 per share, beating the Zacks Consensus Estimate of $3.80 per share. This compares to earnings of $3.33 per share a year ago. These figures are adjusted for non-recurring items.
Synovus Q2 Earnings Beat Estimates, Revenues Fall Y/Y
Synovus Financial Corp. (NYSE: SNV) reported second-quarter 2024 adjusted earnings per share of $1.16, which surpassed the Zacks Consensus Estimate of 96 cents. Adjusted earnings were the same as that reported in the year-ago quarter.
U.S. Silica's Acquisition by Apollo Gets Shareholders' Nod
U.S. Silica Holdings, Inc. (NYSE: SLCA) announced the shareholder approval of its acquisition by funds managed by affiliates of Apollo, a premier investment firm. This all-cash transaction was approved during a special meeting of the company's stockholders on Jul 16, 2024.
WAFD's Q3 Earnings Beat Estimates, Revenues Rise on LBC Deal
WaFd, Inc.'s (NASDAQ: WAFD) third-quarter fiscal 2024 (ended Jun 30) adjusted earnings of 76 cents per share handily surpassed the Zacks Consensus Estimate of 59 cents. Also, the bottom line rose 4.1% sequentially.
Progressive's Q2 Earnings Beat, Premiums Rise Y/Y
The Progressive Corporation's (NYSE: PGR) second-quarter 2024 earnings per share of $2.65 beat the Zacks Consensus Estimate of $1.99. The bottom line improved more than five times year over year.
Lexeo Down Despite Upbeat Rare Disease Gene Therapy Data
Shares of Lexeo Therapeutics (NASDAQ: LXEO) lost 26% on Monday after it reported positive interim data from two cohorts of the phase I/II SUNRISE-FA study evaluating LX2006, an investigational gene therapy for treating Friedreich ataxia (FA) cardiomyopathy.

Explore Benzinga's Financial Tools

Find Stocks Tailored to Your Trading Interests
Find Stocks Tailored to Your Trading Interests
Benzinga Pro offers a real-time newsfeed as headlines break on earnings releases, analyst ratings, rumors, the biggest movers, and many more actionable alerts.

Compare Benzinga's Favorite Brokers

Claim Exclusive Offers

Claim Exclusive Offers

Compare Benzinga's Favorite Cryptocurrency Brokers

Claim Exclusive Offers